NCT03637543 Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03635983 A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma Status COMPLETED Phase PHASE3
NCT03634995 An Investigational Study to Evaluate the Effects of Experimental Medication BMS-986256 in Healthy Participants Status COMPLETED Phase PHASE1
NCT03634969 An Investigational Study to Evaluate Experimental Medication BMS-986224 in Renally Impaired Participants Status COMPLETED Phase PHASE1
NCT03632187 Abatacept in earLy Onset Polymyalgia Rheumatica: Study ALORS Status COMPLETED Phase PHASE3
NCT03631641 Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy Status TERMINATED Phase PHASE2
NCT03630640 Neoadjuvant and Adjuvant Nivolumab in HCC Patients Treated by Electroporation Status TERMINATED Phase PHASE2
NCT03628209 Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT03627806 FLorida Puerto Rico Atrial Fibrillation Stroke Study (FLiPER-AF) Status COMPLETED Phase N/A
NCT03624127 Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis Status COMPLETED Phase PHASE3
NCT03623854 Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma Status COMPLETED Phase PHASE2
NCT03620123 A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck Status COMPLETED Phase PHASE2
NCT03619876 Effects of Abatacept on Myocarditis in Rheumatoid Arthritis Status TERMINATED Phase PHASE4
NCT03611751 An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis Status COMPLETED Phase PHASE3
NCT03611101 Companion Protocol for ¹³C-Methacetin Breath Tests in BMS: NCT03486899, NCT03486912 Referenced Trials Status COMPLETED Phase N/A
NCT03610711 REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT03610490 Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma Status TERMINATED Phase PHASE2
NCT03607890 Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03605927 CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease Status COMPLETED Phase PHASE1